Table 5. Differences in the expanded range after enhancement of malignant lesions compared among different molecular types.
| Factors | Luminal A (n=25) | Luminal B (n=62) | HER2+ (n=21) | TNBC (n=13) | P value |
|---|---|---|---|---|---|
| Longitudinal diameter increment (mm) | 1.37±2.18 | 2.53±2.19 | 3.45±2.44 | 2.85±1.47 | 0.015 |
| Transverse diameter increment (mm) | 5.68±4.43 | 6.13±4.26 | 6.14±4.89 | 6.32±3.99 | 0.967 |
| Area increment (cm2) | 1.10±0.80 | 1.61±0.91 | 1.81±1.18 | 1.50±0.86 | 0.059 |
| Percent increase in longitudinal diameter (%) | 13.10±19.88 | 18.50±16.36 | 23.94±15.36 | 24.33±15.65 | 0.039 |
| Percent increase in transverse diameter (%) | 40.64±33.91 | 34.41±26.67 | 26.01±20.21 | 38.15±28.65 | 0.332 |
| Percent increase in area increment (%) | 71.79±53.95 | 80.64±48.06 | 62.97±40.44 | 85.30±49.23 | 0.352 |
Measurement data (e.g., age) are presented as the mean ± SD. HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; SD, standard deviation.